These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18597835)

  • 21. Is it possible to predict post-residual voided urine by bladder scan before uroflowmetry--a useful and timesaving test to reduce the number of non--evaluable uroflow measurements?
    Dicuio M; Vesely S; Knutson T; Damber JE; Cuzzocrea DE; Dahlstrand C
    Arch Ital Urol Androl; 2010 Jun; 82(2):100-4. PubMed ID: 20812533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study.
    Komiya A; Suzuki H; Awa Y; Egoshi K; Onishi T; Nakatsu H; Ohki T; Mikami K; Sato N; Araki K; Ota S; Naya Y; Ichikawa T
    Int J Urol; 2010 Jun; 17(6):555-62. PubMed ID: 20370847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of high bladder neck elevation with urodynamic bladder outlet obstruction in patients with lower urinary tract symptoms and benign prostatic hyperplasia.
    Kang M; Kim M; Choo MS; Bae J; Ku JH; Yoo C; Oh SJ
    Urology; 2014 Dec; 84(6):1461-6. PubMed ID: 25432841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Stief CG; Porst H; Neuser D; Beneke M; Ulbrich E
    Eur Urol; 2008 Jun; 53(6):1236-44. PubMed ID: 18281145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between Lower Urinary Tract Symptoms (LUTS) and sexual function in benign prostatic hyperplasia: impact of treatment of LUTS on sexual function.
    Jung JH; Jae SU; Kam SC; Hyun JS
    J Sex Med; 2009 Aug; 6(8):2299-304. PubMed ID: 19493292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term treatment and prognostic factors of alpha 1-blockers for lower urinary tract symptoms associated with benign prostatic hyperplasia: a pilot study comparing naftopidil and tamsulosin hydrochloride.
    Kawachi Y; Sakurai T; Sugimura S; Iwata S; Noto K; Honda S; Maruyama O
    Scand J Urol Nephrol; 2010 Feb; 44(1):38-45. PubMed ID: 20095868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms.
    Barqawi AB; Myers JB; O'Donnell C; Crawford ED
    BJU Int; 2007 Oct; 100(4):853-7. PubMed ID: 17662074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. alpha-Blockers improve chronic ischaemia of the lower urinary tract in patients with lower urinary tract symptoms.
    Pinggera GM; Mitterberger M; Pallwein L; Schuster A; Herwig R; Frauscher F; Bartsch G; Strasser H
    BJU Int; 2008 Feb; 101(3):319-24. PubMed ID: 18005199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.
    Matsukawa Y; Gotoh M; Komatsu T; Funahashi Y; Sassa N; Hattori R
    J Urol; 2009 Dec; 182(6):2831-5. PubMed ID: 19837428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glomerulation observed during transurethral resection of the prostate for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia is a common finding but no predictor of clinical outcome.
    Furuya R; Masumori N; Furuya S; Oda T; Takahashi S; Takeuchi M
    Urology; 2007 Nov; 70(5):922-6. PubMed ID: 18068448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is the ultrasound-estimated bladder weight a reliable method for evaluating bladder outlet obstruction?
    Almeida FG; Freitas DG; Bruschini H
    BJU Int; 2011 Sep; 108(6):864-7. PubMed ID: 21166745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of lower urinary tract symptom/benign prostatic hyperplasia measures with international index of erectile function 5 in middle-aged policemen of Korea and the role of metabolic syndrome and testosterone in their relationship.
    Lee JH; Kwon H; Park YW
    Urology; 2013 Nov; 82(5):1008-12. PubMed ID: 24041675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
    Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
    BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment.
    Roehrborn CG; Kaminetsky JC; Auerbach SM; Montelongo RM; Elion-Mboussa A; Viktrup L
    BJU Int; 2010 Feb; 105(4):502-7. PubMed ID: 19732051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of prostatic-urethral angulation on the treatment outcome of patients with symptomatic benign prostatic hyperplasia treated with tamsulosin hydrochloride.
    El-Tatawy H; Gameel T; El-enen MA; Hagras A; Mousa A; El-Bahnasy AH; Raheem AA; Abu-dewan K
    Arch Ital Urol Androl; 2015 Sep; 87(3):238-42. PubMed ID: 26428648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of patient-reported outcome of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and treated with tamsulosin HCl in Korea.
    Chang HS; Park CH; Kim DK; Park JK; Hong SJ; Chung BH; Lee JG; Kim CS; Lee KS; Kim JC
    Urology; 2010 May; 75(5):1156-61. PubMed ID: 19914692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic and predictive value of voiding diary data versus prostate volume, maximal free urinary flow rate, and Abrams-Griffiths number in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    van Venrooij GE; van Melick HH; Eckhardt MD; Boon TA
    Urology; 2008 Mar; 71(3):469-74. PubMed ID: 18342189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the clinical value of a simple flowmeter in the management of male lower urinary tract symptoms.
    Chan CK; Yip SK; Wu IP; Li ML; Chan NH
    BJU Int; 2012 Jun; 109(11):1690-6. PubMed ID: 21933332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.